Personalized Treatments, HER2-Directed Drugs Are Changing the Breast Cancer Space
February 23rd 2020The fields of early-stage hormone receptor (HR)–positive and metastatic HER2-positive breast cancer have made great strides in recent years, said Neelima Denduluri, MD, and such progress could be attributed to the emergence of tailored treatment strategies and the use of HER2-directed agents, respectively.